Active	Status	Sponsor type	Region	Phase	Filter
11 Active 9 Inactive 20 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bao, Ting
CA209-8H3, NCT03650894: Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients	Active, not recruiting	2	30	US	Nivolumab, Opdivo, Ipilimumab, Yervoy, Bicalutamide, Casodex	Providence Health & Services, Bristol-Myers Squibb, Memorial Sloan Kettering Cancer Center	Breast Neoplasm Female, Breast Cancer, Breast Carcinoma, Breast Tumor	01/25	01/26
Tkaczuk, Katherine
KEYNOTE 721, NCT03310957 / 2017-002289-35: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer	Completed	1/2	186	Europe, US, RoW	ladiratuzumab vedotin, LV, SGN-LIV1A, Pembrolizumab, KEYTRUDA®	Seagen Inc., Merck Sharp & Dohme LLC	Triple Negative Breast Neoplasms	09/24	09/24